160 related articles for article (PubMed ID: 28249013)
1. Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia.
Chim L; Salkeld G; Kelly P; Lipworth W; Hughes DA; Stockler MR
PLoS One; 2017; 12(3):e0172971. PubMed ID: 28249013
[TBL] [Abstract][Full Text] [Related]
2. Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia.
Chim L; Salkeld G; Kelly PJ; Lipworth W; Hughes DA; Stockler MR
Aust Health Rev; 2019 Jul; 43(3):254-260. PubMed ID: 29669674
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Eliciting public preferences for healthcare: a systematic review of techniques.
Ryan M; Scott DA; Reeves C; Bate A; van Teijlingen ER; Russell EM; Napper M; Robb CM
Health Technol Assess; 2001; 5(5):1-186. PubMed ID: 11262422
[TBL] [Abstract][Full Text] [Related]
5. Sharing Government Health Data With the Private Sector: Community Attitudes Survey.
Braunack-Mayer A; Fabrianesi B; Street J; O'Shaughnessy P; Carter SM; Engelen L; Carolan L; Bosward R; Roder D; Sproston K
J Med Internet Res; 2021 Oct; 23(10):e24200. PubMed ID: 34596573
[TBL] [Abstract][Full Text] [Related]
6. Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting.
Reckers-Droog V; van Exel J; Brouwer W
PLoS One; 2018; 13(6):e0198761. PubMed ID: 29949648
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
Linley WG; Hughes DA
Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
[TBL] [Abstract][Full Text] [Related]
9. Health versus other sectors: Multisectoral resource allocation preferences in Mukono district, Uganda.
Yemeke TT; Kiracho EE; Mutebi A; Apolot RR; Ssebagereka A; Evans DR; Ozawa S
PLoS One; 2020; 15(7):e0235250. PubMed ID: 32730256
[TBL] [Abstract][Full Text] [Related]
10. Government and charity funding of cancer research: public preferences and choices.
Shah KK; Sussex J; Hernandez-Villafuerte K
Health Res Policy Syst; 2015 Sep; 13():38. PubMed ID: 26335693
[TBL] [Abstract][Full Text] [Related]
11. Patient advocacy group involvement in health technology assessments: an observational study.
Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
[TBL] [Abstract][Full Text] [Related]
12. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
13. Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults.
Darvishi A; Daroudi R; Yaseri M; Sari AA
BMC Public Health; 2022 Nov; 22(1):2038. PubMed ID: 36344950
[TBL] [Abstract][Full Text] [Related]
14. Equal access for equal need: Eliciting public preferences for access to health treatment by employment status.
Gibbs N; Powell PA; Tsuchiya A
Soc Sci Med; 2019 Feb; 222():246-255. PubMed ID: 30665064
[TBL] [Abstract][Full Text] [Related]
15. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
McLeod L; Bereza BG; Shim M; Grootendorst P
Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
[TBL] [Abstract][Full Text] [Related]
16. Who Would Pay Higher Taxes for Better Mental Health? Results of a Large-Sample National Choice Experiment.
Johnson FR; Gonzalez JM; Yang JC; Ozdemir S; Kymes S
Milbank Q; 2021 Sep; 99(3):771-793. PubMed ID: 34375477
[TBL] [Abstract][Full Text] [Related]
17. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
Polisena J; Burgess M; Mitton C; Lynd LD
BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
[TBL] [Abstract][Full Text] [Related]
18. Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.
Dabbous O; Chachoua L; Aballéa S; Sivignon M; Persson U; Petrou S; Richardson J; Simoens S; Toumi M
Adv Ther; 2023 Feb; 40(2):393-424. PubMed ID: 36451072
[TBL] [Abstract][Full Text] [Related]
19. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
